A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Inclusion Criteria:

- Pathologically documented relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
or follicular lymphoma (FL)

- Measurable disease sites on CT scan (>1.5 cm in longest dimension)

- Adequate hematologic function:

1. Absolute Neutrophil Count >1500 cells/mm3

2. Platelets >50000 cells/mm3

3. Hemoglobin >8.0 g/dL

- Adequate hepatic and renal function:

1. AST or ALT ≤2.5 x ULN

2. Bilirubin ≤1.5 x ULN

3. Estimated creatinine clearance (Cockcroft-Gault) >40 mL/min

- ECOG 0 or 1

Exclusion Criteria:

- Received prior therapies: ibrutinib, or other BTK inhibitor and/or anti-PD1,
anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 antibody

- Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor

- Primary CNS lymphoma or evidence of CNS involvement by lymphoma